Skip to main content

Table 1 Characteristics of the newborns in the study cohort

From: Effect of newborn genomic screening for lysosomal storage disorders: a cohort study in China

 

NBGS

NBGS + Enzyme activity detection

No. (%)

(N = 22,687)

All

(N = 900)

Negative a

(N = 290)

Carrier b

(N = 543)

Positive c

(N = 29)

Non-LSD Positive d

(N = 38)

Sex

 Male

11,996 (52.88)

490 (54.44)

158 (54.48)

290 (53.41)

14 (48.28)

28 (73.68)

 Female

10,691 (47.12)

410 (45.56)

132 (45.52)

253 (46.59)

15 (51.72)

10 (26.32)

 Unknown

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

Gestation age

 Preterm (< 37 wk)

857 (3.78)

25 (2.78)

2 (0.69)

19 (3.50)

3 (10.34)

1 (2.63)

 Full term (37–40 wk)

16,511 (72.78)

661 (73.44)

220 (75.86)

396 (72.93)

19 (65.52)

26 (68.42)

 Late term (40.1–42 wk)

5308 (23.40)

214 (23.78)

68 (23.45)

128 (23.57)

7 (24.14)

11 (28.95)

 Post term (> 42 wk)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

 Unknown

11 (0.05)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

Birth weight

 < 2750 g

1469 (6.48)

44 (4.89)

6 (2.07)

34 (6.26)

3 (10.34)

1 (2.63)

 2750–4000 g

21,018 (92.64)

816 (90.67)

276 (95.17)

483 (88.95)

24 (82.76)

33 (86.84)

 > 4000 g

190 (0.84)

40 (4.44)

8 (2.76)

26 (4.79)

2 (6.90)

4 (10.53)

 Unknown

10 (0.04)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

Delivery

 Eutocia

13,224 (58.29)

500 (55.56)

142 (48.97)

325 (59.85)

11 (37.93)

22 (57.89)

 Cesarean

9456

(41.71)

400 (44.44)

148 (51.03)

218 (40.15)

18 (62.07)

16 (42.11)

 Unknown

7 (0.03)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

  1. a “Negative” refers to samples with negative NBGS results; b “Carrier” refers to samples identified as carriers of LSDs based on NBGS results; c “Positive” refers to samples with an NBGS result indicating LSD positivity; d “Non-LSD Positive” refers to samples with positive results for non-LSD diseases and have been clinically diagnosed